#Nodus finance free

The biotech received seed funding from Cumulus Oncology, a Scottish biotech creation studio, and the Lead Discovery Centre (LDC) in Dortmund (Germany). Ma’am, requiescat in pace.Įdinburgh-based Nodus Oncology has emerged from stealth. If organoids is not your thing and but do wonder how machine learning powers biobank-driven drug discovery, scroll in the same direction. If you are either WNT pathway connoisseurs or simply get excited with organoids, the Interesting Readings section features fascinating research this week. Good news for Evox Therapeutics, Biofidelity and Spirea as they all have been granted patents these week. Syncona-backed Purespring Therapeutics has appointed Alice Brown, PhD, former VP of Gene Engineering at GammaDelta Therapeutics and Exscientia has appointed Caroline Rowland as Chief People Officer (CPO). The Pharma section explains (in-a-nutshell) the Illumina/ Grail/ EuropeanCommission/ FederalTradeCommission affair.

#Nodus finance free

If nothing changes, they will need to divest and let Grail free after the European Commission blocked the acquisition. Now, friends, there is a figure larger than $4.6 billion in this week’s edition of Cambridge Biocapital, and that is the $8 billion Illumina payed to (re)acquire Grail. Upwards and onwards, Bessemer Venture Partners has closed $4.6 billion across two new funds. Those interested in academic spin outs, Scotland’s largest company creation programme for the university sector has unveiled the 28 academic finalists that will compete at the Converge 2022 competition. And yet, Oxford Foundry is closing and politics might have played a role. One day we will need to talk about accelerators but meanwhile, know that these have duplicated in number in the past five years. In this case, Arcutis BioTherapeutics has acquired Ducentis BioTherapeutics for up to $400 million (tip: immunological checkpoints!). In London, business carries on as usual with US companies acquiring British biotechs.

Of all the ways to emerge from stealth mode, the one that involves acquiring an entire portfolio of PARP inhibitors from a Switzerland-based pharma ranks pretty high: welcome Nodus Oncology to the Edinburgh-based biotech ecosystem.